Zoetis Inc.
Financials
Valuation Metrics
Zoetis Inc.'s Market Cap is $33.42B. At end of 2025 it was $54.90B. Ranked #432 of 3,116 in US market (top 14%), #304 of 1,644 on NYSE (top 18%), #26 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $33.42B | US#432/3,116 Sec#26/265 |
| Revenue | $9.52B | US#577/3,116 Sec#21/265 |
| Net Income | $2.62B | US#283/3,116 Sec#15/265 |
| Total Assets | $15.08B | US#759/3,116 Sec#24/265 |
| Net Assets | $3.15B | US#938/3,116 Sec#34/265 |
| Employees | 14,500 | US#694/3,116 Sec#22/265 |
| Value | ||
| P/E | 12.77x | US#567/3,116 Sec#18/265 |
| P/B | 10.62x | US#2,631/3,116 Sec#194/265 |
| PEG | 83.44x | US#1,278/3,116 Sec#33/265 |
| P/S | 3.51x | US#1,896/3,116 Sec#60/265 |
| EV/EBITDA | 10.63x | US#880/3,116 Sec#26/265 |
| FCF Yield | 7.08% | US#959/3,116 Sec#29/265 |
| Profitability | ||
| ROE | 83.10% | US#43/3,116 Sec#1/265 |
| ROA | 17.35% | US#164/3,116 Sec#23/265 |
| Op. Margin | 37.00% | US#347/3,116 Sec#20/265 |
| Revenue Growth | 1.41% | US#2,088/3,116 Sec#125/265 |
| Earnings Growth | 0.15% | US#1,284/3,116 Sec#33/265 |
| Financial Health | ||
| Debt Ratio | 378.94% | US#2,240/3,116 Sec#217/265 |
| Total Debt | $9.24B | US#437/3,116 Sec#20/265 |
| FCF | $2.37B | US#316/3,116 Sec#19/265 |
| Cash | $1.48B | US#535/3,116 Sec#25/265 |
| Current Ratio | 3.08x | US#750/3,116 Sec#184/265 |
| Net Debt/EBITDA | 2.00x | US#1,325/3,116 Sec#57/265 |
| Dividend | ||
| Div. Yield | 2.66% | US#697/3,116 Sec#10/265 |
| Div. Growth | 15.85% | US#323/3,116 Sec#3/265 |
| Performance | ||
| 1Y Return | -44.25% | US#2,817/3,116 Sec#233/265 |
| 1M Return | 14.15% | US#563/3,116 Sec#38/265 |
| From 52W High | -44.73% | US#2,544/3,116 Sec#189/265 |
| 1Y MDD | -51.93% | US#2,471/3,116 Sec#172/265 |
| Trading | ||
| Volume | 3,223,652 shares | US#813/3,116 Sec#73/265 |
| Trading Value | $257M | US#590/3,116 Sec#27/265 |
| Per Share | ||
| EPS | $6.24 | US#534/3,116 Sec#18/265 |
| BPS | $7.51 | US#2,035/3,116 Sec#91/265 |
Company Info
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.